EUVIMEDEUVIMED entdecken
Crossref

Preparation and in vitro functional validation of a novel antibody-siRNA-Exatecan conjugate (AREC)

Xiang Yu, Ze Meng Ma, Feng Ji, Mingjiu Chen, Huricha Baigude

International Immunopharmacology · 2026

DOI: 10.1016/j.intimp.2025.115938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Xiang Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry & Chemical Engineering, Inner Mongolia University, Hohhot, Inner Mongolia 010020, PR China; Biosion Inc., Nanjing, Jiangsu, PR Ch…. Hauptthemen laut MEDLINE: RNA, Small Interfering, Immunoconjugates, Camptothecin, Neoplasms. Die Arbeit nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-siRNA conjugate (ARC) is a novel therapeutic strategy developed based on the concept of antibody-drug conjugate (ADC). It combines the targeting specificity of antibodies with the gene silencing ability of small interfering RNA (siRNA) and shows broad application prospects. However, the development of traditional ARC in the field of tumor treatment faces many challenges, and the DNA Topoisomerase I Inhibitor-Exatecan is limited in its clinical application due to its strong hydrophobicity and significant toxicity. In this study, we developed a novel antibody-siRNA-Exatecan conjugate (AREC). By introducing siRNA, we plan to increase the hydrophilicity of small molecule drugs and optimize the drug to antibody ratio (DAR) to 1 and 2. This modification not only significantly reduced the toxic side effects associated with high DAR values, but also provided a basis for evaluating the synergistic anti-tumor effect between STAT3 gene silencing and Exatecan. In vitro experimental results showed that AREC can efficiently kill tumor cells, fully demonstrating its great potential as a multifunctional platform for tumor targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingImmunoconjugatesCamptothecinNeoplasmsHumansSTAT3 Transcription FactorCell Line, TumorGene Silencing

Stichwörter der Autor:innen

ARCExatecanSTAT3siRNA delivery

Substanzen

RNA, Small InterferingImmunoconjugatesSTAT3 Transcription FactorCamptothecinSTAT3 protein, human

Autor:innen und Institutionen

  • School of Chemistry & Chemical Engineering, Inner Mongolia University, Hohhot, Inner Mongolia 010020, PR China; Biosion Inc., Nanjing, Jiangsu, PR China.
  • Biosion Inc., Nanjing, Jiangsu, PR China.
  • Center of Clinical Laboratory Medicine, Jiangbei Campus, Zhongda Hospital, Southeast University, Nanjing 210048, PR China.
  • Biosion Inc., Nanjing, Jiangsu, PR China. Electronic address: mingjiu.chen@biosion.com.
  • School of Chemistry & Chemical Engineering, Inner Mongolia University, Hohhot, Inner Mongolia 010020, PR China. Electronic address: hbaigude@imu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yu, X., Ma, Z. M., Ji, F., Chen, M., & Baigude, H. (2026). Preparation and in vitro functional validation of a novel antibody-siRNA-Exatecan conjugate (AREC). International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115938

Vancouver

Yu X, Ma ZM, Ji F, Chen M, Baigude H. Preparation and in vitro functional validation of a novel antibody-siRNA-Exatecan conjugate (AREC). International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.115938

BibTeX
@article{Yu2026,
  author = {Yu, Xiang and Ma, Ze Meng and Ji, Feng and Chen, Mingjiu and Baigude, Huricha},
  title = {Preparation and in vitro functional validation of a novel antibody-siRNA-Exatecan conjugate (AREC)},
  journal = {International Immunopharmacology},
  year = {2026},
  doi = {10.1016/j.intimp.2025.115938}
}
Kostenlos starten →